About this trial
This study evaluates the effectiveness of Pathfinding, a 6-month, remotely-delivered case management intervention designed to decrease suicidal behavior among active-duty Regular Army soldiers recently discharged from inpatient psychiatric treatment. Soldiers discharged from military treatment facilities across the U.S. will be identified and recruited to participate. Those who consent will be randomly assigned to receive either Treatment As Usual (TAU), which is the Army's standard post-discharge care, or TAU plus Pathfinding. Participants will complete a baseline assessment and follow-up assessments 6 months and 12 months later. The 6- and 12-month follow-up periods will also include examination of participants' electronic healthcare data and Army administrative data. The overall goals of the study are: (1) to evaluate whether Pathfinding decreases suicidal behaviors among soldiers transitioning from psychiatric hospitalization back to the community; and (2) to determine which discharged soldiers are most likely to benefit from the Pathfinding intervention versus TAU alone.
Eligibility criteria
Qualifiers
Active duty Regular Army soldiers recently discharged from inpatient psychiatric care at a military treatment facility in the US
Access to telephone and computer (including smartphone)
Disqualifiers
Impaired ability to provide informed consent
Terminal illness
Failure to complete baseline survey within 30 days of discharge
Positive screen for post-discharge suicide-related behaviors
Trial design
Treatments tested in this trial
- Pathfinding
- Treatment As Usual (TAU)
Treatment groups
Sponsors and collaborators
Uniformed Services University of the Health Sciences
Lead sponsor
Harvard Medical School (HMS and HSDM)
Collaborator
University of Michigan
Collaborator